Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer

Clinical Cancer Research

Volumn 18, Issue 9, 2012, Pages 2668-2678

  Chambers, Setsuko K ^a   Chow, H H Sherry ^a   Janicek, Mike F ^a   Cragun, Janiel M ^a   Hatch, Kenneth D ^a   Cui, Haiyan ^a   Laughren, Cynthia ^a   Clouser, Mary C ^a   Cohen, Janice L ^a   Wright, Heather M ^a   Shahin, Nisreen Abu ^a   Alberts, David S ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; HOMOCYSTEINE; PACLITAXEL; PEMETREXED;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INSOMNIA; LEUKOPENIA; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORAL MUCOSITIS; OUTCOME ASSESSMENT; OVARY CANCER; PATIENT ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; SEIZURE; SENSORY NEUROPATHY; THROMBOCYTOPENIA; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FALLOPIAN TUBE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GLUTAMATES; GUANINE; HUMANS; INJECTIONS, INTRAPERITONEAL; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TISSUE DISTRIBUTION;

EID: 84860530551     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0261     Document Type: Article

References (36)

1. American Cancer Society. Cancer facts & figures 2011. Atlanta, GA: American Cancer Society; 2011.
2. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-5. (Pubitemid 26428219)
3. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson L, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in smallvolume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19: 1001-7. (Pubitemid 32176274)
4. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43. (Pubitemid 43048949)
5. Alberts DS, Chambers SK. Introduction. In:Alberts DS, Clouser MC, Hess LM, editors. Intraperitoneal therapy for ovarian cancer. Heidelberg, Germany: Springer-Verlag; 2010. p. 1-6.
6. Trimble EL, Christian MC. Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma. Gynecol Oncol 2006; 100:3-4. (Pubitemid 41815040)
7. Hess LM, Benham-Hutchins M, Herzog TJ, Hsu CH, Malone DC, Skrepnek GH, et al. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Intl J Gynecol Cancer 2007;17:561-70. (Pubitemid 46744010)
8. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44. (Pubitemid 46606305)
9. Hanna N, Shepherd FA, Fossella FV, Pereira JR, de Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97. (Pubitemid 41079796)
10. Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN, et al. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol 2008;26: 5761-66.
11. Sehouli J, Camara O, Mahner S, Bauknecht T, Lichtenegger W, Runnebaum I, et al. A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer. Cancer Chemother Pharmacol 2010;66: 861-8.
12. Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol 2009;27: 2686-91.
13. Vergote I, Calvert H, Kania M, Kaiser C, Zimmermann AH, Sehouli J. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer 2009;45:1415-23.
14. Hensley ML, Larkin J, Fury M, Gerst S, Tai DF, Sabbatini P, et al. A phase I trial of pemetrexed plus gemcitabine given biweekly with Bvitamin support in solid tumor malignancies or advanced epithelial ovarian cancer. Clin Cancer Res 2008;14:6310-6.
15. Gasent Blesa JM, Alberola Candel V, Provencio Pulla M, Esteban González E, Martín Algarra S. Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine. Clin Transl Oncol 2009;11:35-40.
16. Scagliotti GV, Shin D-M, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:1556-61. (Pubitemid 46594110)
17. Pestieau SR, Stuart OA, Sugarbaker PH. Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model. Eur J Surg Oncol 2000;26:696-700.
18. Thodtmann R, Depenbrock H, Dumez H, Blatter J, Johnson RD, van Oosterom A, et al. Clinical and pharmakokinetic Phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 1999;17:3009-16. (Pubitemid 29470627)
19. Dickgreber NJ, Fink TH, Latz JE, Hossain AM, Musib LC, Thomas M. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer. Clin Cancer Res 2009;15:382-9.
20. Howell SB. Selection of drugs for intraperitoneal chemotherapy for ovarian cancer. In:Alberts DS, Clouser MC, Hess LM, editors. Intraperitoneal therapy for ovarian cancer. Heidelberg, Germany: Springer- Verlag; 2010. p. 77-88.
21. Kano Y, Akutsu M, Tsunoda S, Kobayashi H, Inoue K, Mori K, et al. Schedule-dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro. Oncol Res 2006;16: 85-95.
22. Takimoto CH, Hammond-Thelin LA, Latz JE, Forero L, Beeram M, Forouzesh B, et al. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res 2007;13:2675-83. (Pubitemid 46788035)
23. Rustin GJS, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004;96: 487-8. (Pubitemid 38443654)
24. Stapleton S, Reid J, Thompson P, Ames M, McGovern R, McGuffey L, et al. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. Cancer Chemother Pharmacol 2007;59:461-6. (Pubitemid 46122324)
25. Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1: 545-52.
26. Tiersten AD, Liu PY, Smith HO, Wilczynski SP, Robinson WR III, Markman M, et al. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. Gynecol Oncol 2009;112:444-9.
27. Smith HO, Moon J, Wilczynski SP, Tiersten AD, Hannigan EV, Robinson WR, et al. Southwest Oncology Group Trial S9912: Intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer. Gynecol Oncol 2009; 114:206-9.
28. Seamon LG, Carlson MJ, Richardson DL, Cohn DE, Fowler JM, Copeland LJ, et al. Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer. Intl J Gynecol Cancer 2009;19: 1195-98.
29. Kim S-W, Paek J, Nam E-J, Kim S-H, Kim J-H, Kim Y-T. The feasibility of carboplatin-based intraperitoneal chemotherapy in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2010;152:195-9.
30. Konner JA, Grabon DM, Gerst SR, Iasonos A, Thaler H, Pezzulli SD, et al. Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. J Clin Oncol 2011:29: 4662-68.
31. Berry E, Matthews KS, Singh DK, Buttin BM, Lurain JR, Alvarez RD, et al. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer. Gynecol Oncol 2009;113: 63-7.
32. Dizon DS, Sill MW, Gould N, Rubin SC, Yamada SD, DeBernardo RL, et al. Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2011;123: 182-6.
33. Oaknin A, Desamparado R, Gonzalez-Martin A, Chiva L, Garcia-Donas J, de Juan A, et al. Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study. Intl J Gynecol Cancer 2011;21:1048-55.
34. Bijelic L, Stuart OA, Sugarbaker PH. Intraperitoneal pemetrexed combined with intravenous cisplatin is well tolerated as an adjuvant treatment for diffuse malignant peritoneal mesothelioma. In: Proceedings of the 7th International Workshop for Peritoneal Surface Malignancy; 2010 Sep 8-10; Uppsala, Sweden.
35. Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D, Sugarbaker PH. Heated intraoperative intraperitoneal mitomycin-C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology 1998;55:130-8. (Pubitemid 28052257)
36. de Lima Vasquez V, Stuart OA, Mohamed F, Sugarbaker PH. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Cancer Chemother Pharmacol 2003;52:108-12. (Pubitemid 37041342)